Arbutus Biopharma (ABUS) Cash from Operations (2013 - 2026)
Arbutus Biopharma (ABUS) posted Cash from Operations of 8110000.0 for Q1 2026, down 73.29% sequentially from 4680000.0 in Q4 2025, and up 39.44% YoY from 5816249.46 in Q1 2025.
Arbutus Biopharma (ABUS) Cash from Operations (2013 - 2026) Analysis & Trends
Arbutus Biopharma has reported Cash from Operations for 14 years, with the latest figure at 8110000.0 in Q1 2026.
- Quarterly Cash from Operations rose 39.44% year-over-year to 8110000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34356000.0 (up 41.72% YoY) and the FY2025 annual result came in at 39637000.0, up 38.88% from the prior year.
- Cash from Operations eased to 8110000.0 in Q1 2026 per ABUS's latest filing, from 4680000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 20619000.0 in Q1 2022 and troughed at 27301000.0 in Q1 2023.
- A 5-year average of 13758176.47 and a median of 16990000.0 in 2022 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations jumped 215.31% in 2022, then tumbled 232.41% in 2023.
- Over 5 years, Cash from Operations stood at 16990000.0 in 2022, then dropped by 1.78% to 17292000.0 in 2023, then surged by 40.35% to 10315000.0 in 2024, then jumped by 54.63% to 4680000.0 in 2025, then slumped by 73.29% to 8110000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 8110000.0, 4680000.0, and 5817000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | -6.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.02 Mn |
| Jun 30, 2026 | -6.02 Mn |
| Mar 31, 2026 | -8.11 Mn |
| Mar 31, 2026 | -8.11 Mn |
| Dec 31, 2025 | -4.68 Mn |
| Dec 31, 2025 | -4.68 Mn |
| Sep 30, 2025 | -5.82 Mn |
| Sep 30, 2025 | -5.82 Mn |
| Jun 30, 2025 | -15.75 Mn |
| Jun 30, 2025 | -15.75 Mn |
| Mar 31, 2025 | -13.39 Mn |
| Mar 31, 2025 | -13.39 Mn |
| Dec 31, 2024 | -10.32 Mn |
| Dec 31, 2024 | -10.32 Mn |
| Sep 30, 2024 | -20.74 Mn |
| Sep 30, 2024 | -20.74 Mn |
| Jun 30, 2024 | -14.50 Mn |
| Jun 30, 2024 | -14.50 Mn |
| Mar 31, 2024 | -19.30 Mn |
| Mar 31, 2024 | -19.30 Mn |